Zydus Lifesciences Gets Usfda Nod To Market Generic Version Of Colestipol Hydrochloride Tablets Colestipol Hydrochloride Tablets
Zydus Lifesciences Ltd On Monday Said It Has Received The Final Approval From The Us Health Regulator To Market Its Generic Version Of Colestipol Hydrochloride Tablets, Which Is Used To Lower Cholesterol. The Approval By The Us Food And Drug Administration Is For Colestipol Hydrochloride Of 1 Mg Strength, The Company Said In A Regulatory Filing. Colestipol Hydrochloride Tablets Are Indicated As Adjunctive Therapy To Diet Reduction Of Elevated Serum Total And Ldl-C (Low-Density Lipoprotein, Known As Bad Cholesterol) In Patients With Primary Hypercholesterolemia (Elevated Ldl-C) Who Do Not Respond Adequately To Diet, It Added. "Zydus' Anda Is Only The Second Generic Application Approved By Usfda For This Product," It Said.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!